Page 22 of 43

April 10, 2021

Moderna Antibody Studies 6 Months After Vaccination

More Good News!  This week Moderna published antibody levels measured over 6 months after the 2nd dose in their Phase 1 trial and they were excellent and durable.  All of the tests were done at NIH-NIAID.  These were the volunteers that participated in the very first human studies.  Phase 1 clinical vaccine trials are done to assess safety and to establish a dose range that produces a good antibody response.  Now this small patient group has been observed and their antibody production measured regularly for just over 6 months from their vaccination.  In contrast, Phase 3 clinical vaccine studies assess the ability of vaccination to prevent symptomatic infection in vaccinated subjects compared to subjects given placebo - and then vaccine efficacy is calculated. 

In the current report antibody production to the "spike proteins" and the efficacy of the subjects serum to neutralize the virus was assessed serially by 3 different types of tests on 33 volunteers over a 6 month period.  There were 3 age groups tested: 18-55 years, 56-70 years, and 71+ years.  There was an excellent antibody response in all subjects and it remained high over 6 months in all age groups, although the amount of antibodies decreased with advancing age.  The antibody amounts that best correlate with vaccine efficacy are not currently known, but this patient cohort will continue to be monitored, and will even be given a booster dose to assess its effect on antibody production against the virus and the variants.   Even more good news: see below.


Yesterday Pfizer submitted a request to the FDA to extend their EUA for approval of their vaccine for 12-15 year old children.   There were ~2000 children studied and there was an immune response in 100% of the children.  Antibody levels were even higher than in older groups. That means 3 more of our grandchildren will be eligible!

April 7, 2021

Wonderful Pfizer and Moderna Vaccine Data

There was a CDC Vaccination Study Published in the Morbidity and Mortality Weekly Report from April 2 - and the results are very encouraging.  Health Care Workers, 1st responders, and other essential/frontline workers (N=3950 subjects) were randomized between Moderna/Pfizer vaccinations and placebo.  Eight locations in 6 states participated in the Heroes-Recover study from Dec. 14, 2020 to Mar. 13, 2021 (AZ, FL, MN, OR, TX, and UT).  The subject ages included 72% 18-49 years and 28% >50. 

All of the subjects were Covid-19 PCR test negative prior to their vaccinations and then a  nasal swab Covid-19 PCR test was repeated weekly for 13 weeks and if they developed symptoms during that time. The symptoms surveyed include fever, chills, cough, shortness of breath, sore throat, diarrhea, myalgias, and/or loss of taste or smell.  The Phase 3 Clinical Trials for both vaccines studied volunteers when they developed symptoms and this study provides data for the protection against asymptomatic and symptomatic subjects.  Thirty-one percent had at least 1 comorbidity.  See Below for Results


The Good News:  Subjects who were >2 weeks following their 2nd dose (N=2470 subjects) had 90% efficacy preventing symptomatic and asymptomatic Covid-19 compared to placebo.  For those that were >2 weeks after just a single dose (N=477 subjects) had an efficacy of 80%. 


April 3, 2021

Great News From Pfizer!

Great News!  Pfizer just updated their Covid Vaccine Phase 3 clinical trial data after 6 months.  This information was published in a company press release.  They found 927 cases of symptomatic and confirmed cases of Covid-19 in their clinical trial subjects- 850 cases in the placebo group and 77 in the vaccinated group - for an efficacy of 91.3%  Protection against severe disease in vaccinated subjects was 100% using the CDC criteria (32 cases) and 95.3% using the FDA criteria of severe disease (21 cases).  There were safety data on more than 12,000 vaccinated subjects who were followed for at least 6 months after their 2nd dose and the safety profile was still favorable.  These data will make it possible to apply for a Biologic License Approval (BLA) from the FDA - based on their 6 month safety follow-up.  A BLA is required for commercial advertising and distribution. 

In the US trial there were 647 Covid cases in the placebo group, 50 in the vaccine group for an efficacy of 92.6%  In the S. African trial of about 800 volunteers there were 9 cases of Covid-19 in the placebo group, 6 of whom had the S. African variant.  There were no safety issues in the full trial of approximately 44,000 volunteers.  All vaccinated volunteers will be followed for a full 24 months to collect additional data. Read Below 


The Pfizer vaccine EUA was granted one week before the Moderna vaccine, so we may see the 6 month followup data for the Moderna vaccine shortly.  One of the requirements for submitting an application for a BLA is having 6 months of follow-up safety data.  The Moderna trial will also be carried out for a full 24 months.  This is deemed important for all clinical trials because very rare side effects could still be seen.


March 31, 2021

Vaccine Trial in Pregnant Women and Their Babies

Clinical vaccine trials are rarely done in pregnant women, or children, until there are substantial safety data.  This week a prospective cohort study of pregnant women was reported in a preprint from two of the Harvard hospitals.  There were 84 pregnant patients, 31 lactating patients. and 16 non pregnant reproductive age controls.  Titers of SARS-CoV-2 antibodies were measured in serum samples and breast milk at 4 times, including at delivery.  Umbilical cord sera were also collected at delivery.  Antibody measurements were compared to pregnant women 4-12 weeks after they had Covid-19.

Patients in this study had antibody titers in serum and breast milk after vaccination that were comparable to the antibody titers measured in non-pregnant vaccinated patients and all of the titers were higher than those induced by Covid-19 infection. Antibodies were also present in the umbilical cord samples at the time of delivery.  The Pfizer-BioNTech and Moderna vaccines were known to be safe in pregnant women, but this study demonstrates that the immune response is as robust as in non-pregnant patients and the babies are probably protected for some period of time due to the antibodies passed to them from the mother during the pregnancy and in breast milk. This is the largest study to date of vaccinated pregnant women.  See Below


 It would be wonderful to have this type of data earlier during an epidemic or pandemic, but pregnant women aren't studied until the safety of the vaccines is known - when millions have been vaccinated.  The number of pregnancy complications in these vaccinated patients, like miscarriage and gestational diabetes, were comparable to those in non-vaccinated patients.  Thousands of pregnant women were already vaccinated, safely, but this trial confirmed the excellent immune response in pregnant women and newborn babies. Pfizer has started a clinical trial of their vaccine in 4000 pregnant women so more data will be available later this year.  But at least physicians now have trial data to reassure their pregnant patients about the benefits of the vaccine. 

March 27, 2021

Breakthrough Covid-19 Infections After Vaccination

Although both Moderna and Pfizer vaccines both had efficacy of 94-95% in their clinical trials, people aren't protected fully until at least 2 weeks after their 2nd vaccine dose.  Now we are getting reports of the vaccine performance in the real world in millions of patients.  In California (UC LosAngeles and UC SanDiego) and Texas (Univ of Texas Southwestern Medical Center) health care workers were vaccinated and then tested regularly to detect Covid-19.  The number of cases decreased beginning 2 weeks after the first dose and most importantly maximal protection occurred at 2 weeks after the second dose.  

The incidence was reduced to 0.05% (of approximately 10,000 HCW) in both studies and with both vaccines.  There is a 3rd recent report from Hadassah Medical Center in Jerusalem with similar results with the Pfizer vaccine,  and at that time the B.1.1.7 variant (UK) was 80% of infections locally.  Read More Below


Breakthrough cases can occur in people who have an immune deficiency disorder or because their bodies cannot produce a robust immune reaction, which can be seen in elderly patients.  Examination of virus samples from breakthrough patients will give us information about the current vaccines ability to prevent infection with the new variants.  In order to analyze that data virus samples need to be saved for genomic sequencing, a complex process.   There is no current evidence that the breakthrough cases are due to the circulating variants, but the CDC has ramped up genomic testing of coronavirus patient samples to map the spread of the variants and especially those in breakthrough cases.

I've been following the SARS-CoV-2 variants present locally.  This week, ending March 23rd, a subset of 1481 patient samples from the NYC Health and Hospital facilities (inpatients and outpatients)  were analyzed in the NYC Pandemic Response Lab.  Variants present included UK Variant (141), California variants (15), Brazilian variant (1) and New York City variant (481).  There were no S. African variants detected.  I hope this information will be helpful for my friends that live in this area.  I'm still following the CDC mitigation guidelines for vaccinated people.